# US 10,369,157 B1 · Multi-agent formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,369,157 B1
- Document ID: US10369157B1
- Status: Granted
- Kind: B1
- Application number: 15/940,141
- Filed: 2018-03-29
- Granted: 2019-08-06
- Earliest claimed: 2018-03-29
- Assignees: Mfkc 200, LLC
- Applicants: Mauricio Androvandi
- Inventors: Mauricio Androvandi
- Web page: https://patentgrep.com/patent/US10369157B1

## CPC

- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/4168: having a nitrogen attached in position 2, e.g. clonidine
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A multi-agent formulation for intravenous administration comprising an active component and an inert carrier solution. The active component comprises a plurality of constituents, including at least a sleep inducing agent, an analgesic agent, an anesthetic agent, and an adrenergic agonist agent. The sleep inducing agent comprises Midazolam, the analgesic agent comprises Fentanyl, the anesthetic agent comprises Ketamine, and the adrenergic agonist agent comprises Clonidine. The active component comprises the following amounts, indicated as a percentage of the weight of the active component: approximately 4.75% of the sleep inducing agent, approximately 0.10% of the analgesic agent, approximately 95.08% of the anesthetic agent, and approximately 0.07% of the adrenergic agonist agent.

## Claims

### Claim 1

A standard unit dosage per 10 kilograms of a patient's body weight of a multi-agent formulation for inducing a state of sedation and/or a state of anesthesia in the patient comprising:
approximately 0.5 mg of 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4] benzodiazepine, approximately 10 μg of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide, approximately 10 mg of 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one, and approximately 7.5 μg of N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine.

### Claim 2

A multi-agent formulation for inducing a state of sedation and/or a state of anesthesia in a patient, said formulation comprising:
an active component comprising approximately 4.75% by weight of 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4] benzodiazepine, approximately 0.1% by weight of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide, approximately 95.08% by weight of 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one, approximately 0.07% by weight of N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine, and
an inert carrier solution.